The best treatment for depression is a combination of therapy and medication, which consistently outperforms either approach on its own. In long-term studies, people who received both psychotherapy and antidepressants had roughly 40% fewer relapses than those treated with medication alone. But “best” depends on severity, personal preferences, and how your body responds, so understanding what each option actually delivers will help you find the right fit.
Why Combined Treatment Works Best
A meta-analysis of 19 randomized controlled trials found that combining psychotherapy with antidepressants was significantly better than medication alone at preventing relapse, recurrence, and rehospitalization. The combination cut the risk of relapse by about 40% compared to antidepressants by themselves. Interestingly, the outcomes for combined treatment and therapy alone were statistically similar in the long run, suggesting that therapy carries much of the lasting benefit.
One study tracking patients for two years after inpatient treatment found that those who received group therapy alongside their medication had significantly fewer rehospitalizations: 27% compared to 40% for medication with clinical management alone. Another trial of remitted patients showed that combined treatment reduced relapse rates over 12 months so substantially that only five people needed to be treated to prevent one additional relapse. The pattern is clear: medication can lift you out of an episode, but therapy helps you stay out.
What Therapy Looks Like
The two most studied forms of therapy for depression are cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). Both work well, but they target different things. CBT focuses on identifying and restructuring negative thought patterns and building healthier daily habits. IPT focuses on improving relationships and resolving interpersonal conflicts that feed depression.
In a head-to-head trial, 76% of CBT participants and 79% of IPT participants reached the threshold for meaningful improvement on a standard depression scale. IPT showed a slight edge in reducing core depressive symptoms and feelings of hopelessness, while CBT was more effective at improving general well-being. In practice, the differences are small enough that the best therapy is often the one that resonates with you and that you’ll actually stick with. If your depression is tangled up in relationship problems or grief, IPT may be a natural fit. If it’s driven more by negative self-talk and avoidance, CBT is a strong choice.
How Antidepressants Compare
The most commonly prescribed antidepressants fall into two main categories. SSRIs increase the availability of serotonin in the brain. SNRIs do the same but also boost norepinephrine, a chemical involved in energy and alertness. A meta-analysis of 15 head-to-head trials involving over 3,000 patients found remission rates of about 49% for SNRIs and 42% for SSRIs. That roughly 6% difference was statistically significant but not considered clinically meaningful, meaning either class is a reasonable starting point.
SNRIs did come with a tradeoff: dropout rates due to side effects were about 3% higher than with SSRIs. Among the roughly 700 patients surveyed in a real-world study of SSRIs, 38% reported at least one side effect. The most common were changes in sexual functioning, sleepiness, and weight gain. These side effects are a major reason people stop taking antidepressants, so having an honest conversation about what to expect is important before starting.
One thing that catches many people off guard is how long antidepressants take to work. SSRIs can take up to six weeks before you feel the full therapeutic effect. Early weeks may bring side effects without noticeable mood improvement, which is discouraging but normal. Sticking with the medication through that window, with your prescriber’s guidance, gives it a fair chance to work.
Exercise as a Standalone or Add-On
For mild to moderate depression, regular exercise performs roughly as well as antidepressants in clinical trials. Three randomized controlled trials comparing four months of aerobic exercise (walking, jogging, or cycling three times per week) to standard antidepressant treatment found them equally effective. Reviews of the broader evidence confirm this pattern: for mild to moderate depression, exercise is a comparable alternative, while for severe depression it works best as a complement to other treatments.
The most striking data comes from a trial in older adults with major depression. Those who did high-intensity aerobic exercise alongside their antidepressant achieved remission at a rate of 81%, compared to 73% for low-intensity exercise plus medication and just 45% for medication alone. That’s a dramatic gap. Even low-intensity exercise nearly doubled the remission rate compared to medication by itself. The takeaway is straightforward: whatever else you’re doing for your depression, adding consistent physical activity meaningfully improves your odds.
Options When Standard Treatment Falls Short
About one-third of people with depression don’t respond adequately to first-line treatments. This is sometimes called treatment-resistant depression, generally defined as failing to improve after trying at least two different antidepressants. For these cases, there are more intensive options.
Electroconvulsive therapy (ECT) remains the most effective intervention for severe, treatment-resistant depression. It achieves a response rate of about 64% and a remission rate of 53%. Modern ECT is done under general anesthesia and is far different from its historical reputation. Side effects can include short-term memory issues around the time of treatment, and sessions typically happen two to three times per week for several weeks.
Transcranial magnetic stimulation (TMS) is a noninvasive alternative that uses magnetic pulses to stimulate specific areas of the brain. It doesn’t require anesthesia, and you’re awake during sessions. Response rates are lower than ECT, around 49%, with remission in about 32% of patients. For people who want to avoid anesthesia or the cognitive side effects of ECT, TMS is a reasonable middle ground.
A nasal spray containing esketamine, a derivative of the anesthetic ketamine, is approved for treatment-resistant depression. It’s administered in a clinical setting, typically twice a week for the first month, then tapering to once a week or every two weeks. Unlike standard antidepressants, esketamine can produce noticeable mood improvement within hours to days rather than weeks. You’re required to stay at the clinic for monitoring after each dose because the drug can cause dissociation and sedation.
Psilocybin Therapy: Early but Promising
Psilocybin, the active compound in certain mushrooms, is generating serious clinical interest. In a randomized trial of 30 healthcare workers with moderate to severe depression that developed during the pandemic, psilocybin therapy produced a 21-point drop on a standard depression scale, compared to a 9-point drop in the control group. For context, a 6 to 9-point change on that scale is considered clinically meaningful, so a 21-point reduction is substantial. No serious adverse events occurred in the trial.
Psilocybin works on serotonin receptors and appears to promote neuroplasticity, essentially helping the brain form new connections. However, it’s not yet FDA-approved for depression, and treatment involves supervised sessions with trained therapists rather than something you’d take at home. Access is currently limited to clinical trials and a handful of jurisdictions with specific legal frameworks.
Matching Treatment to Severity
Mild depression often responds well to therapy alone or to structured lifestyle changes like regular exercise, consistent sleep, and social engagement. Starting with therapy gives you skills that protect against future episodes without the side effects of medication.
Moderate depression is where the combination of therapy and medication shows its strongest advantage. The medication provides enough neurochemical support to engage meaningfully in therapy, and the therapy builds the cognitive and behavioral changes that prevent relapse after medication ends.
Severe depression, especially when it involves inability to function, significant weight changes, or thoughts of self-harm, typically requires medication as a first step simply because the person may not be able to participate fully in therapy until their symptoms are partially managed. For the most severe and treatment-resistant cases, ECT, TMS, or esketamine become important options. The goal at every level is the same: get to a place where you can function, then build the habits and skills that keep you there.